Unveiling the paradigm shift: systemic treatment strategies in small, node-negative breast cancer
Abstract The implementation of screening mammography has significantly altered the size distribution of breast tumors, with approximately 20% of newly diagnosed breast cancers measuring 10 mm or smaller with node-negative disease (T1aN0 and T1bN0). The management of these early-stage breast cancers...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-05-01
|
| Series: | npj Breast Cancer |
| Online Access: | https://doi.org/10.1038/s41523-025-00761-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849734161883987968 |
|---|---|
| author | Mariana Carvalho Gouveia Mariana Scaranti Bruna Migliavacca Zucchetti Renata Colombo Bonadio Romualdo Barroso-Sousa Jose Pablo Leone |
| author_facet | Mariana Carvalho Gouveia Mariana Scaranti Bruna Migliavacca Zucchetti Renata Colombo Bonadio Romualdo Barroso-Sousa Jose Pablo Leone |
| author_sort | Mariana Carvalho Gouveia |
| collection | DOAJ |
| description | Abstract The implementation of screening mammography has significantly altered the size distribution of breast tumors, with approximately 20% of newly diagnosed breast cancers measuring 10 mm or smaller with node-negative disease (T1aN0 and T1bN0). The management of these early-stage breast cancers remains a subject of debate. Historically, patients with T1aN0 and T1bN0 breast cancer have been excluded from adjuvant chemotherapy trials due to their excellent prognosis, with reported 10-year disease-specific survival rates exceeding 90%. However, the optimal treatment strategy for this subgroup of patients continues to be controversial, as the potential benefits of adjuvant chemotherapy must be carefully weighed against the risks of overtreatment. In this review, we summarize current evidence on outcomes and treatment strategies, highlight gaps in the literature, and provide future perspectives on the management of T1aN0 and T1bN0 breast cancer, according to immunohistochemical subtypes. |
| format | Article |
| id | doaj-art-d4f38d8c4f094adcae150c6a7df15002 |
| institution | DOAJ |
| issn | 2374-4677 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Breast Cancer |
| spelling | doaj-art-d4f38d8c4f094adcae150c6a7df150022025-08-20T03:07:51ZengNature Portfolionpj Breast Cancer2374-46772025-05-011111610.1038/s41523-025-00761-8Unveiling the paradigm shift: systemic treatment strategies in small, node-negative breast cancerMariana Carvalho Gouveia0Mariana Scaranti1Bruna Migliavacca Zucchetti2Renata Colombo Bonadio3Romualdo Barroso-Sousa4Jose Pablo Leone5Department of Medical Oncology, DASA OncologyDepartment of Medical Oncology, DASA OncologyDepartment of Medical Oncology, DASA OncologyDepartment of Medical Oncology, Instituto D’Or de Pesquisa e Ensino (IDOR)Department of Medical Oncology, DASA Oncology, Brasília Hospital, DASADepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical SchoolAbstract The implementation of screening mammography has significantly altered the size distribution of breast tumors, with approximately 20% of newly diagnosed breast cancers measuring 10 mm or smaller with node-negative disease (T1aN0 and T1bN0). The management of these early-stage breast cancers remains a subject of debate. Historically, patients with T1aN0 and T1bN0 breast cancer have been excluded from adjuvant chemotherapy trials due to their excellent prognosis, with reported 10-year disease-specific survival rates exceeding 90%. However, the optimal treatment strategy for this subgroup of patients continues to be controversial, as the potential benefits of adjuvant chemotherapy must be carefully weighed against the risks of overtreatment. In this review, we summarize current evidence on outcomes and treatment strategies, highlight gaps in the literature, and provide future perspectives on the management of T1aN0 and T1bN0 breast cancer, according to immunohistochemical subtypes.https://doi.org/10.1038/s41523-025-00761-8 |
| spellingShingle | Mariana Carvalho Gouveia Mariana Scaranti Bruna Migliavacca Zucchetti Renata Colombo Bonadio Romualdo Barroso-Sousa Jose Pablo Leone Unveiling the paradigm shift: systemic treatment strategies in small, node-negative breast cancer npj Breast Cancer |
| title | Unveiling the paradigm shift: systemic treatment strategies in small, node-negative breast cancer |
| title_full | Unveiling the paradigm shift: systemic treatment strategies in small, node-negative breast cancer |
| title_fullStr | Unveiling the paradigm shift: systemic treatment strategies in small, node-negative breast cancer |
| title_full_unstemmed | Unveiling the paradigm shift: systemic treatment strategies in small, node-negative breast cancer |
| title_short | Unveiling the paradigm shift: systemic treatment strategies in small, node-negative breast cancer |
| title_sort | unveiling the paradigm shift systemic treatment strategies in small node negative breast cancer |
| url | https://doi.org/10.1038/s41523-025-00761-8 |
| work_keys_str_mv | AT marianacarvalhogouveia unveilingtheparadigmshiftsystemictreatmentstrategiesinsmallnodenegativebreastcancer AT marianascaranti unveilingtheparadigmshiftsystemictreatmentstrategiesinsmallnodenegativebreastcancer AT brunamigliavaccazucchetti unveilingtheparadigmshiftsystemictreatmentstrategiesinsmallnodenegativebreastcancer AT renatacolombobonadio unveilingtheparadigmshiftsystemictreatmentstrategiesinsmallnodenegativebreastcancer AT romualdobarrososousa unveilingtheparadigmshiftsystemictreatmentstrategiesinsmallnodenegativebreastcancer AT josepabloleone unveilingtheparadigmshiftsystemictreatmentstrategiesinsmallnodenegativebreastcancer |